How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
67
FBRX Quote, Financials, Valuation and Earnings
Last price:
$34.75
Seasonality move
:
5.23%
Day range:
$28.89 - $35.50
52-week range:
$4.90 - $35.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.14x
Volume:
357.9K
Avg. volume:
218.3K
1-year change:
117.05%
Market cap:
$432.1M
Revenue:
--
EPS (TTM):
-$4.44
Analysts' Opinion
-
Consensus RatingForte Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $63.75, Forte Biosciences, Inc. has an estimated upside of 84.84% from its current price of $34.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $54.00 representing 100% downside risk from its current price of $34.49.
Fair Value
-
According to the consensus of 5 analysts, Forte Biosciences, Inc. has 84.84% upside to fair value with a price target of $63.75 per share.
FBRX vs. S&P 500
-
Over the past 5 trading days, Forte Biosciences, Inc. has overperformed the S&P 500 by 6.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Forte Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Forte Biosciences, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Forte Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Forte Biosciences, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Forte Biosciences, Inc. reported earnings per share of -$0.99.
Enterprise value:
338.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$55K
Return On Assets:
-77.96%
Net Income Margin (TTM):
--
Return On Equity:
-91.42%
Return On Invested Capital:
-91.42%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3K | -$35K | -$55K | -$10K | -$17K | |
| Operating Income | -$31M | -$35.6M | -$53.4M | -$8.6M | -$18.4M | |
| EBITDA | -$31M | -$35.6M | -$53.4M | -$8.6M | -$18.4M | |
| Diluted EPS | -$30.98 | -$19.39 | -$4.44 | -$4.54 | -$0.99 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $46.6M | $44.6M | $47.1M | $17.7M | $95.4M | |
| Total Assets | $47.4M | $45.1M | $47.9M | $17.9M | $97.1M | |
| Current Liabilities | $3.7M | $2.3M | $7.5M | $8.6M | $13M | |
| Total Liabilities | $3.7M | $2.3M | $7.5M | $8.6M | $13M | |
| Total Equity | $43.7M | $42.8M | $40.4M | $9.4M | $84.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.6M | -$29.7M | -$44.4M | -$8.1M | -$14M | |
| Cash From Investing | $63K | -$22K | $247K | -- | -$55K | |
| Cash From Financing | $24.7M | -$95K | $121.2M | -$2K | $1.3M | |
| Free Cash Flow | -$22.7M | -$29.7M | -$44.6M | -$8.1M | -$14.1M | |
FBRX
Sector
Market Cap
$432.1M
$24M
Price % of 52-Week High
96.83%
50%
Dividend Yield
0%
0%
Shareholder Yield
-64.55%
-1.68%
1-Year Price Total Return
117.06%
-21.15%
Beta (5-Year)
3.216
0.502
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$31.85
200-day SMA
Buy
Level
$14.54
Bollinger Bands (100)
Buy
Level
11.89 - 26.37
Chaikin Money Flow
Buy
Level
516.9K
20-day SMA
Buy
Level
$29.87
Relative Strength Index (RSI14)
Buy
Level
61.40
ADX Line
Buy
Level
16.11
Williams %R
Sell
Level
-12.6116
50-day SMA
Buy
Level
$25.14
MACD (12, 26)
Buy
Level
5.92
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
411.5K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.1477)
Sell
CA Score
(Annual)
Level (-2.0347)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.2244)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.
Stock Forecast FAQ
In the current month, FBRX has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FBRX average analyst price target in the past 3 months is $63.75.
-
Where Will Forte Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Forte Biosciences, Inc. share price will rise to $63.75 per share over the next 12 months.
-
What Do Analysts Say About Forte Biosciences, Inc.?
Analysts are divided on their view about Forte Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Forte Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $54.00.
-
What Is Forte Biosciences, Inc.'s Price Target?
The price target for Forte Biosciences, Inc. over the next 1-year time period is forecast to be $63.75 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is FBRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Forte Biosciences, Inc. is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FBRX?
You can purchase shares of Forte Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Forte Biosciences, Inc. shares.
-
What Is The Forte Biosciences, Inc. Share Price Today?
Forte Biosciences, Inc. was last trading at $34.75 per share. This represents the most recent stock quote for Forte Biosciences, Inc.. Yesterday, Forte Biosciences, Inc. closed at $34.49 per share.
-
How To Buy Forte Biosciences, Inc. Stock Online?
In order to purchase Forte Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get FBRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FBRX
Sector
P/E ratio
--
23.60x
PEG ratio
--
-0.01x
P/B ratio
5.14x
1.78x
Price / LTM sales
--
1.53x
Growth Metrics
FBRX
Sector
Revenue growth
--
3.96%
Earnings growth
78.12%
10.7%
Revenue (5-year growth)
--
6.15%
Earnings forecast
-$1.18
-$0.19
Profitability
FBRX
Sector
Profitability FY 2024
-$39K
$2.9M
Return on invested capital
-91.42%
-33.43%
Return on assets
-77.96%
-29.68%
Return on equity
-91.42%
-38.98%
Earnings Date
Last Earnings Date
Feb
3
Next Earnings Date
Feb
3
Estimated Next Earnings Date
May
5
Balance Sheet
FBRX
Sector
Total cash
$93.4M
$24.9M
Short term investments
$36.1M
$23.9M
Total assets
$61.6M
$71.9M
Long term debt
--
$2.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 43x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 43x
Alerts
Sell
49
HYMC alert for Feb 3
Hycroft Mining Holding Corp. [HYMC] is down 5.78% over the past day.
Buy
67
FBRX alert for Feb 3
Forte Biosciences, Inc. [FBRX] is up 18.72% over the past day.
Buy
72
BNR alert for Feb 3
Burning Rock Biotech Ltd. [BNR] is up 11.66% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
